Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $39.86.

ORKA has been the subject of a number of analyst reports. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 7th.

Insider Buying and Selling

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 8,971 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $11.86 per share, with a total value of $106,396.06. Following the completion of the transaction, the insider now directly owns 4,044,684 shares of the company's stock, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders purchased 98,339 shares of company stock valued at $1,128,456. Insiders own 22.67% of the company's stock.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $54,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $144,000. Squarepoint Ops LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $303,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Trading Up 1.1 %

ORKA stock opened at $11.06 on Wednesday. The stock has a market capitalization of $387.09 million, a P/E ratio of -1.77 and a beta of 0.67. Oruka Therapeutics has a 52 week low of $9.44 and a 52 week high of $31.13. The business's 50-day moving average is $12.94.

Remove Ads

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19. As a group, analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.